Effects of Darbepoetin Alfa with exercise in cancer patients undergoing chemotherapy: an explorative study

Fatigue is frequent in cancer patients undergoing chemotherapy. Erythropoietins (EPO) have shown well-documented effects on these patients, and administered in pharmacological doses, may reduce the need for transfusion of blood cells and improve quality of life (QoL). An explorative, descriptive, non-randomised intervention study using semi-structured interviews was conducted with the aim to gain an insight into the effects and experiences associated with EPO treatment in combination with a structured 6-week physical exercise intervention. Sixteen cancer patients with evidence of disease, who had received at least one cycle chemotherapy, participated. Participants received 500 [mu]g Darbepoetin Alfa (DA) every 3 weeks during the intervention. Four typologies of patients were identified with regard to DA effects. The interviews revealed that eleven patients experienced some kind of immediate improvement in cognitive and emotional functioning, and subjective daily well-being. Furthermore physical improvement and changes in QoL outcomes showed no significant differences between the study group and a reference group. A significant increase in the hemoglobin concentration was found in the study group.

The future use of EPO in cancer patients is hampered by the reported negative influence of EPO on the prognosis in some diagnoses and should be based on randomized studies.

M. Rørth, K. R. Madsen, S. H. Burmølle, J. Midtgaard, C. Andersen, B. Nielsen, M. Stage, L. Adamsen. Effects of Darbepoetin Alfa with exercise in cancer patients undergoing chemotherapy: an explorative study.  Scandinavian Journal of Medicine & Science in Sports, 31 Jan 2010, online article ahead of print

Related posts:

1. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.
2. Efficacy of Intra-Articular Botulinum Toxin Type A in Painful Knee Osteoarthritis: A Pilot Study.
3. Self-reported outcomes during treatment with tumour necrosis factor [agr] inhibitors in patients with rheumatoid arthritis
4. Withdrawal of Analgesic Medication for Chronic Low-Back Pain Patients: Improvement in Outcomes of Multidisciplinary Rehabilitation Regardless of Surgical History.
5. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial